Management tracks: Coles to lead Cerevel; plus Genfit, Jubilant, Paratek, Mogrify, Dementia Discovery Fund and Ayala

Cerevel Therapeutics LLC (Boston, Mass.) hired Tony Coles as CEO. Coles is Cerevel’s executive chairman as well as the co-founder and executive chairman of neurodegeneration company Yumanity Therapeutics LLC (Cambridge, Mass.), where he was until recently CEO (see “Coles Picks Peters to Lead Company”).

Coles was chairman and CEO of Onyx Pharmaceuticals Inc., prior to its 2013 acquisition by Amgen Inc. (NASDAQ:AMGN) for $10.4 billion.

The move comes three weeks after Cerevel hired Orly Mishan as CBO. She was principal and a founding member of Bain Capital Life Sciences, which launched the Pfizer Inc. (NYSE:PFE) spinout with $350 million in funding last year to develop the pharma’s discontinued neurological disease pipeline (see “Springing into Cerevel”).

Carol Addy joined Genfit S.A. (Euronext:GNFT; NASDAQ:GNFT) as CMO. Addy was CMO of Health Management Resources, a subsidiary of Merck & Co. Inc. (NYSE:MRK), and previously served as associate director, director and senior principal scientist at Merck Research Laboratories. She will be based in the metabolic and liver related disease company’s Cambridge, Mass. office.

Jubilant Life Sciences Ltd. (BSE:530019; NSE:JUBILANT) said Syed Kazmi will become president and CEO of its new U.S.-based subsidiary Jubilant Therapeutics Inc. He was VP, global head of business development and licensing for oncology at Novartis AG (NYSE:NVS; SIX:NOVN). Jubilant Therapeutics is developing small molecule therapies for cancer and autoimmune disease.

Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) said co-founder Stuart Levy has passed away. Levy co-founded the antibiotics company in 1996 with Walter Gilbert and helped develop Nuzyra omadacycline and Seysara sarecycline, which were approved last year for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSIs), and acne vulgaris, respectively. He is credited with discovering the efflux mechanism of tretracycline resistance and has been honored by the American Society for Microbiology.

Cell therapy company Mogrify Ltd. (Cambridge, U.K.) appointed Jane Osbourn chair. She was VP for R&D and site leader at MedImmune LLC and is chair of U.K.'s BioIndustry Association (BIA).

Christian Jung has joined the Dementia Discovery Fund as partner. He was principal at Wellington Partners Life Sciences.

Cancer company Ayala Pharmaceuticals Inc. (Rehovot, Israel) hired Gary Gordon as CMO. He was VP of oncology development at AbbVie Inc. (NYSE:ABBV).

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE